MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Last update at 2024-07-25T16:52:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -221.70000M | 314.40M | 407.20M | 77.40M | 81.50M |
| Minority interest | - | - | - | - | - |
| Net income | -223.80000M | 230.90M | 305.10M | 54.50M | 62.70M |
| Selling general administrative | 340.30M | 347.50M | 303.30M | 273.50M | 202.50M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 427.20M | 1035.20M | 1031.40M | 672.50M | 460.10M |
| Reconciled depreciation | 143.30M | 123.80M | 114.50M | 110.70M | 62.20M |
| Ebit | -166.00000M | 352.60M | 433.80M | 114.10M | 91.40M |
| Ebitda | -34.40000M | 514.40M | 553.00M | 226.50M | 116.40M |
| Depreciation and amortization | 131.60M | 161.80M | 119.20M | 112.40M | 25.00M |
| Non operating income net other | -11.70000M | -3.70000M | 4.70M | 1.70M | 1.60M |
| Operating income | -166.00000M | 352.60M | 433.80M | 114.10M | 89.80M |
| Other operating expenses | 1286.90M | 1398.40M | 1121.60M | 991.90M | 692.60M |
| Interest expense | 37.30M | 34.50M | 31.30M | 38.40M | 9.90M |
| Tax provision | 2.10M | 83.50M | 102.10M | 22.90M | 18.80M |
| Interest income | 37.30M | 34.50M | 31.30M | 38.40M | 9.90M |
| Net interest income | -37.30000M | -34.50000M | -31.30000M | -38.40000M | -9.90000M |
| Extraordinary items | - | - | - | 0.00000M | 4.30M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 2.10M | 83.50M | 102.10M | 22.90M | 18.80M |
| Total revenue | 1120.90M | 1792.70M | 1555.40M | 1106.00M | 782.40M |
| Total operating expenses | 593.20M | 640.90M | 597.60M | 558.40M | 370.30M |
| Cost of revenue | 693.70M | 757.50M | 524.00M | 433.50M | 322.30M |
| Total other income expense net | -55.70000M | -38.20000M | -26.60000M | -36.70000M | 1.60M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -223.80000M | 230.90M | 305.10M | 100.30M | 62.70M |
| Net income applicable to common shares | -223.80000M | 230.90M | 305.10M | 54.50M | 62.70M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3166.60M | 3166.60M | 2959.00M | 2883.20M | 2329.30M |
| Intangible assets | 728.80M | 728.80M | 604.60M | 663.10M | 741.90M |
| Earning assets | - | - | - | - | - |
| Other current assets | 57.90M | 57.90M | 70.50M | 36.70M | 20.60M |
| Total liab | 1783.60M | 1783.60M | 1340.00M | 1436.20M | 1240.80M |
| Total stockholder equity | 1383.00M | 1383.00M | 1619.00M | 1447.00M | 1088.50M |
| Deferred long term liab | - | 71.80M | 94.90M | 53.20M | 63.90M |
| Other current liab | 142.70M | 169.10M | 72.90M | 83.10M | 6.70M |
| Common stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Capital stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Retained earnings | 734.00M | 734.00M | 957.80M | 726.90M | 421.80M |
| Other liab | - | 90.40M | 156.80M | 210.70M | 199.90M |
| Good will | 218.20M | 218.20M | 224.90M | 266.70M | 268.60M |
| Other assets | - | 191.30M | 57.30M | 115.00M | 65.60M |
| Cash | 642.60M | 642.60M | 576.10M | 621.30M | 167.80M |
| Cash and equivalents | - | 642.60M | 576.10M | 621.30M | 167.80M |
| Total current liabilities | 1229.90M | 1229.90M | 373.80M | 384.50M | 216.30M |
| Current deferred revenue | 26.40M | - | 140.40M | 131.50M | 101.90M |
| Net debt | 763.20M | 763.20M | 264.90M | 253.50M | 643.50M |
| Short term debt | 957.30M | 957.30M | 31.60M | 33.80M | 12.90M |
| Short long term debt | 413.70M | 957.30M | 31.60M | 33.80M | 12.90M |
| Short long term debt total | 1405.80M | 1405.80M | 841.00M | 874.80M | 811.30M |
| Other stockholder equity | 645.80M | 645.80M | 677.20M | 745.30M | 676.50M |
| Property plant equipment | - | 817.60M | 800.10M | 644.10M | 542.30M |
| Total current assets | 1210.70M | 1210.70M | 1272.10M | 1195.90M | 686.20M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 1383.00M | 1619.00M | 1447.00M | 1088.50M |
| Short term investments | 8.50M | - | - | - | - |
| Net receivables | 158.40M | 158.40M | 274.70M | 230.90M | 275.30M |
| Long term debt | 446.50M | 448.50M | 809.40M | 841.00M | 798.40M |
| Inventory | 351.80M | 351.80M | 350.80M | 307.00M | 222.50M |
| Accounts payable | 103.50M | 103.50M | 128.90M | 136.10M | 94.80M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 3.10M | 3.10M | -16.10000M | -25.30000M | -9.90000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.10M | 0.10M | 0.10M | 0.10M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 734.00M | 957.80M | 726.90M | 421.80M |
| Treasury stock | - | -227.70000M | -152.20000M | -39.60000M | -39.60000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 191.30M | 191.30M | 57.30M | 113.40M | 76.90M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1955.90M | 1955.90M | 1686.90M | 1687.30M | 1643.10M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 448.50M | 809.40M | 841.00M | 798.40M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 178.30M | -381.30000M | -225.00000M | -151.00000M | -96.90000M |
| Change to liabilities | - | -52.00000M | -7.70000M | 61.00M | 5.60M |
| Total cashflows from investing activities | - | -381.30000M | -225.00000M | -151.00000M | -96.90000M |
| Net borrowings | - | 564.20M | -35.90000M | 54.50M | 13.70M |
| Total cash from financing activities | 481.20M | 481.20M | -141.00000M | 69.50M | -35.90000M |
| Change to operating activities | - | -86.50000M | -29.90000M | 12.00M | -38.30000M |
| Net income | -223.80000M | -223.80000M | 230.90M | 305.10M | 54.50M |
| Change in cash | 66.30M | 66.30M | -45.20000M | 453.50M | 55.60M |
| Begin period cash flow | 576.30M | 576.30M | 621.50M | 168.00M | 112.40M |
| End period cash flow | 642.60M | 642.60M | 576.30M | 621.50M | 168.00M |
| Total cash from operating activities | -34.10000M | -34.10000M | 321.10M | 536.00M | 188.00M |
| Issuance of capital stock | 8.40M | 0.00000M | 0.00000M | - | - |
| Depreciation | 143.30M | 143.30M | 123.80M | 114.50M | 110.70M |
| Other cashflows from investing activities | - | -21.80000M | -21.80000M | -10.00000M | -10.00000M |
| Dividends paid | 5.00M | - | 15.90M | 17.80M | 0.80M |
| Change to inventory | -51.90000M | -51.90000M | -44.00000M | -83.20000M | -16.70000M |
| Change to account receivables | 114.70M | 114.70M | -48.20000M | 49.00M | -8.20000M |
| Sale purchase of stock | -82.10000M | -82.10000M | -106.00000M | -13.80000M | -7.40000M |
| Other cashflows from financing activities | 597.10M | 597.10M | -35.00000M | 456.60M | 80.40M |
| Change to netincome | - | 41.80M | 118.70M | 104.10M | 62.20M |
| Capital expenditures | 115.80M | 115.80M | 225.00M | 141.00M | 86.90M |
| Change receivables | - | 114.70M | -48.20000M | 49.00M | -8.20000M |
| Cash flows other operating | - | -10.30000M | -56.50000M | -18.00000M | -23.10000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 65.80M | -44.90000M | 454.50M | 55.20M |
| Change in working capital | 0.50M | 0.50M | -94.70000M | 8.80M | -39.90000M |
| Stock based compensation | 45.10M | 45.10M | 42.40M | 51.80M | 26.70M |
| Other non cash items | 19.80M | 19.80M | -28.20000M | 59.00M | 37.60M |
| Free cash flow | -149.90000M | -149.90000M | 96.10M | 395.00M | 101.10M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EBS Emergent Biosolutions Inc |
0.61 4.42% | 14.42 | - | 7.94 | 0.10 | 0.17 | 0.84 | -1.6519 |
| ZTS Zoetis Inc |
5.84 3.25% | 185.50 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.06 0.18% | 33.64 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-1.18 0.73% | 160.95 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.14 0.99% | 13.71 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
400 Professional Drive, Gaithersburg, MD, United States, 20879
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert G. Kramer Sr. | CEO, Pres & Exec. Director | 1957 |
| Mr. Richard S. Lindahl | Exec. VP, CFO & Treasurer | 1964 |
| Mr. Adam R. Havey | Exec. VP & COO | 1971 |
| Mr. Atul Saran | Exec. VP & Chief Strategy and Devel. Officer | 1973 |
| Mr. Robert G. Burrows | VP of Investor Relations | NA |
| Ms. Jennifer L. Fox | Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. | NA |
| Ms. Coleen Glessner | Exec. VP of Global Quality and Ethics & Compliance | NA |
| Ms. Lynn Kieffer | VP of Corp. Communications | NA |
| Ms. Katherine Strei | Exec. VP of HR & Chief HR Officer | 1962 |
| Mr. Richard S. Lindahl M.B.A. | Executive VP, CFO & Treasurer | 1964 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...